Abstract
Chronic diabetic complications affect multiple organ systems and lead to significant morbidity and mortality in the diabetic population. Diabetic cardiomyopathy is a major etiologic factor causing heart failure. Dysfunction of both vascular endothelial cells and cardiomyocytes contributes in the pathogenesis of diabetic cardiomyopathy. Hyperglycemia has been identified as the key determinant in the development of several chronic diabetic complications. Hyperglycemia leads to oxidative stress and several other abnormalities causing changes in cellular signaling. These diabetes-mediated biochemical anomalies show cross-interaction and complex interplay. Such changes also cause alteration of transcriptional and post-transcriptional machinery causing altered production of vasoactive and cardioactive factors. In this review, we will highlight some of the important signaling changes leading to diabetic cardiomyopathy and discuss possible potential therapeutic remedies.
Similar content being viewed by others
References
Sicree R, Shaw J, Zimmet P, Tapp R (2003) The global burden of diabetes. In: Gan D (ed) Diabetes atlas, 2nd edn. International Diabetes Federation, Brussels, pp 15–71
Garcia MJ, McNamara PM, Gordon T, Kannel WB (1974) Morbidity and mortality in diabetics in the Framingham population: 16 year follow-up study. Diabetes 23:105–111
Consensus statement (1993) Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. American Diabetes Association. Diabetes Care 16:72–78
Hayat SA, Patel B, Khattar RS, Malik RA (2004) Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 10:539–557
Bell DS (1995) Diabetic cardiomyopathy A unique entity or a complication of coronary artery disease? Diabetes Care 18:708–714
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602
Cosson S, Kevorkian JP (2003) Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 29:455–466
Hamby RI, Zoneraich S, Sherman L (1974) Diabetic cardiomyopathy. JAMA 229:1749–1754
Factor SM, Minase T, Sonnenblick EH (1980) Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J 99:446–458
Factor SM, Okun EM, Minase T (1980) Capillary microaneurysms in the human diabetic heart. N Engl J Med 302:384–388
Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R (1985) Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1:43–47
Sutherland CG, Fisher BM, Frier BM, Dargie HJ, More IA, Lindop GB (1989) Endomyocardial biopsy pathology in insulin-dependent diabetic patients with abnormal ventricular function. Histopathology 14:593–602
Yarom R, Zirkin H, Stammler G, Rose AG (1992) Human coronary microvessels in diabetes and ischaemia Morphometric study of autopsy material. J Pathol 166:265–270
Okada H, Woodcock MJ, Mitchell J, Sakamoto T, Marutsuka K, Sobel BE et al (1998) Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. Circulation 97:2175–2182
Okruhlicova L, Tribulova N, Weismann P, Sotnikova R (2005) Ultrastructure and histochemistry of rat myocardial capillary endothelial cells in response to diabetes and hypertension. Cell Res 15:532–538
Popov D, Sima A, Stern D, Simionescu M (1996) The pathomorphological alterations of endocardial endothelium in experimental diabetes and diabetes associated with hyperlipidemia. Acta Diabetol 33:41–47
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
UKPDS Group (1999) Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control. Diabetes Care 22:1125–1136
Jugdutt BI (2003) Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough? Circulation 108:1395–1403
Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13:1637–1652
Mandarino LJ, Finlayson J, Hassell JR (1994) High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. Invest Ophthalmol Vis Sci 35:964–972
Kaiser N, Sasson S, Feener EP et al (1993) Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 42:80–89
Lopaschuk GD (2002) Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7:149–159
Taegtmeyer H, McNulty P, Young ME (2002) Adaptation and maladaptation of the heart in diabetes, part I: general concepts. Circulation 105:1727–1733
Stanley WC, Lopaschuk GD, McCormack JG (1997) Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34:25–33
McGavock JM, Victor RG, Unger RH et al (2006) Adiposity of the heart, revisited. Ann Intern Med 144:517–524
Sharma S, Adrogue JV, Golfman L et al (2004) Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18:1692–1700
Endoh M (2006) Signal transduction and Ca2+ signaling in intact myocardium. J Pharmacol Sci 100:525–537
Cesario DA, Brar R, Shivkumar K (2006) Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin North Am 35:601–610
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
Cai L, Kang YJ (2001) Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 1:181–193
Khan ZA, Farhangkhoee H, Chakrabarti S (2006) Towards newer molecular targets for chronic diabetic complications. Curr Vasc Pharmacol 4:45–57
King GL, Loeken MR (2004) Hyperglycemia-induced oxidative stress in diabetic complications. Histochem Cell Biol 122:333–338
Krutzfeldt A, Spahr R, Mertens S et al (1990) Metabolism of exogenous substrates by coronary endothelial cells in culture. J Mol Cell Cardiol 22:1393–1404
Florey L (1966) The endothelial cell. Br Med J 2:487–490
Nishikawa T, Edelstein D, Du XL, Yamagishi SI, Matsumura T, Kaneda Y et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787–790
Griendling KK, FitzGerald GA (2003) Oxidative stress and cardiovascular injury I basic mechanisms and in vivo monitoring of ROS. Circulation 108:1912–1916
van de Ree MA, Huisman MV, de Man FH, van der Vijver JC, Meinders AE, Blauw GJ (2001) Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc Res 52:299–305
Dogra G, Rich L, Stanton K, Watts GF (2001) Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 44:593–601
Lambert J, Aarsen M, Donker AJ, Stehouwer CD (1996) Endothelium-dependent and -independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16:705–711
Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA (1993) Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88:2510–2516
McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR et al (1992) Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771–776
Farhangkhoee H, Khan ZA, Mukherjee S et al (2003) Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 35:1439–1448
Srivastava SK, Ramana KV, Chandra D, Srivastava S, Bhatnagar A (2003) Regulation of aldose reductase and the polyol pathway activity by nitric oxide. Chem Biol Interact 143–144:333–340
Schaffer SW, Jong CJ, Mozaffari M (2012) Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited. Vascul Pharmacol 57:139–149
Ogita H, Liao J (2004) Endothelial function and oxidative stress. Endothelium 11:123–132
Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T (1996) Endothelial nitric oxide synthase targeting to caveolae specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 271:22810–22814
Feron O, Saldana F, Michel JB, Michel T (1998) The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 273:3125–3128
Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski VA, Tu YH et al (1994) Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 126:111–126
Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ (2000) High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 275:11278–11283
Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA (1993) CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 268:11811–11816
Farhangkhoee Y, Khan ZA, Chakrabarti S (2005) Glucose-induced upregulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction. Diabetologia 48:1401–1410
Ting HH, Timimi FK, Boles KS et al (1996) Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 97:22–28
Timimi FK, Ting HH, Haley EA, Roddy MA, Ganz P, Creager MA (1998) Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 31:552–557
Marchioli R (1999) Antioxidant vitamins and prevention of cardiovascular disease: laboratory epidemiological and clinical trial data. Pharmacol Res 40:227–238
Ain SK, McVie R, Jaramillo JJ, Palmer M, Smith T, Meachum ZD et al (1996) The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids 31:S87–S90
Maxwell SRJ (1999) Antioxidant vitamin supplements. Drug Saf 21:253–266
Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294–299
Vlassara H (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17:436–443
Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 280:E685–E694
John WG, Lamb EJ (1993) The Maillard or browning reaction in diabetes. Eye 7:230–237
Raj DS, Choudhury D, Welbourne TC, Levi M (2000) Advanced glycation end products: a Nephrologist’s perspective. Am J Kidney Dis 35:365–380
Skovsted IC, Christensen M, Breinholt J, Mortensen SB (1998) Characterisation of a novel AGE-compound derived from lysine and 3-deoxyglucosone. Cell Mol Biol 44:1159–1163
Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9
Miyata T, Kurokawa K, Van YDSC (2000) Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 9:1744–17452
Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 18:785–792
Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315–1321
Airaksinen KE, Salmela PI, Linnaluoto MK, Ikaheimo MJ, Ahola K, Ryhanen LJ (1993) Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 27:942–945
McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW et al (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91:2470–2478
Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR et al (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463–2469
Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21:3–12
Norton GR, Candy G, Woodiwiss AJ (1996) Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93:1905–1912
Thornalley PJ (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand) 44:1013–1023
Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S et al (1997) Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46:1881–1887
Cooper ME (2004) Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Am J Hypertens 17:31S–38S
Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T et al (2002) Advanced glycation end product-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34:1425–1431
Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF et al (2003) Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol 285:H2587–H2591
Srivastava SK, Ansari NH, Liu S, Izban A, Das B, Szabo G et al (1989) The effect of oxidants on biomembranes and cellular metabolism. Mol Cell Biochem 19:149–157
Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al (1993) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801–813
Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA et al (2004) Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 27:448–454
Ramasamy R, Oates PJ, Schaefer S (1997) Aldose reductase inhibition protects diabetic and non-diabetic rat hearts from ischemic injury. Diabetes 46:292–300
Trueblood N, Ramasamy R (1998) Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol 275:H75–H83
Tang WH, Cheng WT, Kravtsov GM, Tong XY, Hou XY, Chung SK, Chung SS (2010) Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am J Physiol Cell Physiol 299:643–653
Giles TD, Ouyang J, Kerut EK, Given MB, Allen GE, McIlwain EF et al (1998) Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat. Am J Physiol 274:H295–H307
Guo M, Wu MH, Korompai F, Yuan SY (2003) Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol Genomics 12:139–146
Liu X, Wang J, Takeda N, Binaglia L, Panagia V, Dhalla NS (1999) Changes in cardiac protein kinase C activities and isozymes in streptozotocin-induced diabetes. Am J Physiol 277:E798–E804
Way KJ, Katai N, King GL (2001) Protein kinase C and the development of diabetic vascular complications. Diabet Med 18:945–959
Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ et al (2002) Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51:2709–2718
Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A et al (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728–731
Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866
Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332:281–292
Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL (1992) Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89:11059–11063
Pastukh V, Wu S, Ricci C, Mozaffari M, Schaffer S (2005) Reversal of hyperglycemic preconditioning by angiotensin II: role of calcium transport. Am J Physiol Heart Circ Physiol 288:1965–1975
Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD et al (1997) Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 19:9320–9325
Yuan SY, Ustinova EE, Wu MH, Tinsley JH, Xu W, Korompai FL et al (2000) Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res 87:412–417
Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N et al (2003) Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14:S227–S232
Malhotra A, Begley R, Kang BP, Rana I, Liu J, Yang G et al (2005) PKC{epsilon} dependent survival signals in the diabetic heart. Am J Physiol. doi:101152/ajpheart012002004
Xin X, Khan ZA, Chen S, Chakrabarti S (2004) Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis. Lab Invest 84:1451–1459
Wold LE, Ren J (2004) Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun 318:1066–1071
Rodrigues B, Cam MC, McNeill JH (1998) Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180:53–57
Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence mechanisms and therapeutic implications. Endocr Rev 25:543–567
Nakayama H, Morozumi T, Nanto S, Shimonagata T, Ohara T, Takano Y et al (2001) Abnormal myocardial free fatty acid utilization deteriorates with morphological changes in the hypertensive heart. Jpn Circ J 9:783–787
Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M et al (2000) High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939–1945
Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM et al (2005) Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 25:989–994
Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD (2000) Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 49:1231–1238
de Kreutzenberg SV, Crepaldi C, Marchetto S, Calo L, Tiengo A, Del Prato S et al (2000) Plasma free fatty acids and endothelium-dependent vasodilation: effect of chain-length and cyclooxygenase inhibition. J Clin Endocrinol Metab 85:793–798
Stanley WC, Marzilli M (2003) Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 17:133–145
Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M (2003) Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 28:16
Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M et al (2004) Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25:1814–1821
Li SH, McNeill JH (2001) In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 217:121–129
Ren J, Pulakat L, Whaley-Connell A, Sowers JR (2010) Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) 88:993–1001
Francis GA, Annicotte JS, Auwerx J (2003) PPAR-a effects on the heart and other vascular tissues. Am J Physiol 285:H1–H9
Gilde AJ, Bilsen M (2003) Peroxisome proliferator-activated receptors (PPARs): regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand 178:425–434
Lee CH, Olson P, Evans RM (2003) Lipid metabolism metabolic diseases and peroxisome proliferator-activated receptors. Endocrinology 144:2201–2207
Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A et al (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121–130
Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A et al (2003) A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100:1226–1231
Liu Y, Zhu Y, Rannou F, Lee TS, Formentin K, Zeng L et al (2004) Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 110:1128–1133
Hallsten K, Virtanen KA, Lonnqvist F, Janatuinen T, Turiceanu M, Ronnemaa T et al (2004) Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 21:1280–1287
Decker P, Muller S (2002) Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 3:275–283
Du XL, Edelstein D, Rossetti L et al (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing. Proc Natl Acad Sci USA 97:12222–12226
Garcia SF, Virag L, Jagtap P et al (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108–113
Zanetti M, Sato J, Katusic ZS et al (2000) Gene transfer of endothelial nitric oxide synthase alters endothelium-dependent relaxations in aortas from diabetic rabbits. Diabetologia 43:340–347
Feng B, Chen S, Chiu J et al (2008) Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab 294:E1119–E1126
Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C (2002) The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:514–521
Szabo C (2002) PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 4:197–205
Masutani M, Suzuki H, Kamada N, Watanabe M, Ueda O, Nozaki T et al (1999) Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96:2301–2304
Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S et al (1999) Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96:3059–3064
Wang C, George B, Chen S, Feng B, Li X, Chakrabarti S (2012) Genotoxic stress and activation of novel DNA repair enzymes in human endothelial cells and in the retinas and kidneys of streptozotocin diabetic rats. Diabetes Metab Res Rev 28:329–337
Wakasaki H, Koya D, Schoen FJ et al (1997) Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94:9320–9325
Khan ZA, Chan BM, Uniyal S et al (2005) EDB fibronectin and angiogenesis—a novel mechanistic pathway. Angiogenesis 8:183–196
Khan ZA, Farhangkhoee H, Mahon JL et al (2006) Endothelins: regulators of extracellular matrix protein production in diabetes. Exp Biol Med (Maywood) 231:1022–1029
Quehenberger P, Bierhaus A, Fasching P et al (2000) Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49:1561–1570
Chen S, Feng B, George B et al (2010) Transcriptional co-activator p300 regulates glucose induced gene expression in the endothelial cells. Am J Physiol Endocrinol Metab 298:E127–E137
Wilson KD, Li Z, Wagner R et al (2008) Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality. PLoS ONE 3:e2609
Kaur H, Chen S, Xin X et al (2006) Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300. Diabetes 55:104–111
Bowie A, O’Neill LA (2000) Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59:13–23
Baeuerle PA, Baltimore D (1996) NF-kappa B: 10 years after. Cell 87:13–20
Suzuki YJ, Packer L (1993) Inhibition of NF-kappa B DNA binding activity by alphatocopheryl succinate. Biochem Mol Biol Int 31:693–700
Nadler J, Winer L (1996) Free radicals, nitric oxide, and diabetic complications. In: LeRoith D, Taylor SI, Olefsky JM (eds) Diabetes mellitus: a fundamental and clinical text. Lippincott-Raven, Philadelphia, pp 840–848
Chen S, Khan ZA, Cukiernik M et al (2003) Differential activation of NF-kappa Band AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 284:E1089–E1097
Shaulian E, Karin M (2001) AP-1 in cell proliferation and survival. Oncogene 20:2390–2400
Chinenov Y, Kerppola TK (2001) Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20:2438–2452
Bakiri L, Lallemand D, Bossy-Wetzel E et al (2000) Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J 19:2056–2068
Shaulian E, Schreiber M, Piu F et al (2000) The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 103:897–907
McKinsey TA, Zhang CL, Olson EN (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 27:40–47
Youn HD, Grozinger CM, Liu JO (2000) Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4. J Biol Chem 275:22563–22567
Youn HD, Chatila TA, Liu JO (2000) Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J 19:4323–4331
Czubryt MP, Olson EN (2004) Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy. Recent Prog Horm Res 59:105–124
Pikkarainen S, Tokola H, Kerkela R et al (2004) GATA transcription factors in the developing and adult heart. Cardiovasc Res 63:196–207
Morin S, Paradis P, Aries A et al (2001) Serum response factor-GATA ternary complex required for nuclear signaling by a G-protein-coupled receptor. Mol Cell Biol 21:1036–1044
He Q, Lapointe MC (2001) Src and Rac mediate endothelin-1 and lysophosphatidic acid stimulation of the human brain natriuretic peptide promoter. Hypertension 37:478–484
Morimoto T, Hasegawa K, Kaburagi S et al (2000) Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 275:13721–13726
Wei JQ, Shehadeh LA, Mitrani JM et al (2008) Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 118:934–946
Kerkela R, Pikkarainen S, Majalahti-Palviainen T et al (2002) Distinct roles of mitogen activated protein kinase pathways in GATA-4 transcription factor mediated regulation of B-type natriuretic peptide gene. J Biol Chem 277:13752–13760
He X, Kan H, Cai L, Ma Q (2009) Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol 46:47–58
Tan Y, Ichikawa T, Li J, Si Q, Yang H, Chen X, Goldblatt CS, Meyer CJ, Li X, Cai L, Cui T (2011) Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 60:625–633
Yanazume T, Morimoto T, Wada H et al (2003) Biological role of p300 in cardiac myocytes. Mol Cell Biochem 248:115–119
McKinsey TA, Olson EN (2005) Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 115:538–546
McKinsey TA, Olson EN (2004) Cardiac histone acetylation—therapeutic opportunities abound. Trends Genet 20:206–213
Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553–1577
Avantaggiati ML, Carbone M, Graessmann A et al (1996) The SV40 large T antigen and adenovirus E1a oncoproteins interact with distinct isoforms of the transcriptional co-activator, p300. EMBO J 15:2236–2248
Arias J, Alberts AS, Brindle P et al (1994) Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370:226–229
Chen LF, Greene WC (2003) Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med 81:549–557
Zhong H, May MJ, Jimi E et al (2002) The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9:625–636
Giordano A, Avantaggiati ML (1999) p300 and CBP: partners for life and death. J Cell Physiol 181:218–230
Yamashita K, Discher DJ, Hu J et al (2001) Molecular regulation of the endothelin-1 gene by hypoxia: contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem 276:12645–12653
Feng B, Chen S, George B et al (2010) miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 26:40–49
Zhang CL, McKinsey TA, Chang S et al (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479–488
Fischle W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15:172–183
Verdin E, Dequiedt F, Kasler HG (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19:286–293
Chang S, McKinsey TA, Zhang CL et al (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467–8476
Bush E, Fielitz J, Melvin L et al (2004) A small molecular activator of cardiac hypertrophy uncovered in a chemical screen formodifiers of the calcineurin signaling pathway. Proc Natl Acad Sci USA 101:2870–2875
Chuang JC, Jones PA (2007) Epigenetics and MicroRNAs. Pediatr Res 61:24R–29R
Chen JF, Mandel EM, Thomson JM et al (2006) The role of microRNA-1 and microRNA-133 in skeletal muscleproliferation and differentiation. Nat Genet 38:228–233
Saito Y, Liang G, Egger G et al (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogeneBCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435–443
Scott GK, Mattie MD, Berger CE et al (2006) Rapid alteration of microRNAlevels by histone deacetylase inhibition. Cancer Res 66:1277–1281
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463
van Rooij E, Sutherland LB, Liu N et al (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255–18260
Cheng Y, Ji R, Yue J et al (2007) MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 170:1831–1840
van Rooij E, Sutherland LB, Qi X et al (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316:575–579
Carè A, Catalucci D, Felicetti F et al (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613–618
Xiao J, Luo X, Lin H et al (2007) MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 282:12363–12367
Wang XH, Qian RZ, Zhang W et al (2009) MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol 36:181–188
Matkovich SJ, Wang W, Tu Y et al (2010) MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106:166–175
Feng B, Chen S, McArthur K, Wu Y, Sen S, Ding Q, Feldman RD, Chakrabarti S (2011) miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 60:2975–2984
Engerman RL, Kern TS (1987) Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36:808–812
Reddy MA, Villeneuve LM, Wang M et al (2008) Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res 103:615–623
Villeneuve LM, Reddy MA, Lanting LL et al (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 105:9047–9052
Brasacchio D, Okabe J, Tikellis C et al (2009) Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58:1229–1236
El-Osta A, Brasacchio D, Yao D et al (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409–2417
Acknowledgments
The authors acknowledge grant supports from the Canadian Diabetes Association the Canadian Institutes of Health Research, Heart and Stroke Foundation.
Conflict of interest
The authors have no conflict of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mortuza, R., Chakrabarti, S. Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy. Heart Fail Rev 19, 75–86 (2014). https://doi.org/10.1007/s10741-013-9381-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-013-9381-z